Abstract：
Limited tissue in biopsies of malignant bone lesions can preclude definitive subclassification, especially when cellular or matrix elements are sparse, absent, or confounding. It is uncertain whether immunohistochemistry for SOX9 (marker of chondrogenesis) and SATB2 (marker of osteoblastic differentiation) may be discriminatory tools toward osteosarcoma and chondrosarcoma. This study interrogated the preresection biopsies of a cohort of osteosarcoma and chondrosarcoma with SATB2 and SOX9 in tandem, to assess their value as diagnostic adjuncts as well as their concordance with the final resection diagnoses. SATB2 was expressed more frequently in osteosarcoma (46/53, 86%) than in chondrosarcoma (9/18, 50%); SOX9 was expressed in high frequencies in both osteosarcoma (52/53, 98%) and chondrosarcoma (17/18, 94%), and SATB2 and SOX9 were coexpressed in both osteosarcoma (46/53, 89%) and chondrosarcoma (8/18, 44%). There exists significant overlap in the expression of SATB2 and SOX9 in osteosarcoma and chondrosarcoma. These markers are not expressed in a distribution that is unique enough for application toward this particular diagnostic differential.
摘要：
恶性骨病变活检中的有限组织可以排除明确的亚分类，特别是当细胞或矩阵元素稀疏时，缺席,或混淆。尚不确定SOX9（软骨形成标志物）和SATB2（成骨细胞分化标志物）的免疫组织化学是否可能是对骨肉瘤和软骨肉瘤的区分工具。这项研究询问了一组SATB2和SOX9串联的骨肉瘤和软骨肉瘤的切除前活检，评估其作为诊断辅助手段的价值以及与最终切除诊断的一致性。SATB2在骨肉瘤（46/53，86％）中的表达频率高于软骨肉瘤（9/18，50％）；SOX9在骨肉瘤（52/53，98％）和软骨肉瘤（17/18，94％）中均以高频率表达。SATB2和SOX9在骨肉瘤（46/53，89％）和软骨肉瘤（8/18，44％）中共表达。SATB2和SOX9在骨肉瘤和软骨肉瘤中的表达存在明显重叠。这些标记物没有以足够独特的分布表达,以应用于这种特定的诊断差异。
